Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Free Cash Flow (2020 - 2025)

Mirum Pharmaceuticals has reported Free Cash Flow over the past 6 years, most recently at $5.5 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $5.5 million for Q4 2025, up 207.45% from a year ago — trailing twelve months through Dec 2025 was $54.9 million (up 488.01% YoY), and the annual figure for FY2025 was $54.9 million, up 488.01%.
  • Free Cash Flow for Q4 2025 was $5.5 million at Mirum Pharmaceuticals, down from $39.5 million in the prior quarter.
  • Over the last five years, Free Cash Flow for MIRM hit a ceiling of $39.5 million in Q3 2025 and a floor of -$40.2 million in Q2 2021.
  • Median Free Cash Flow over the past 5 years was -$17.8 million (2023), compared with a mean of -$13.0 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 135.81% in 2021 and later surged 938.5% in 2025.
  • Mirum Pharmaceuticals' Free Cash Flow stood at -$33.2 million in 2021, then fell by 4.11% to -$34.5 million in 2022, then soared by 51.85% to -$16.6 million in 2023, then surged by 69.38% to -$5.1 million in 2024, then skyrocketed by 207.45% to $5.5 million in 2025.
  • The last three reported values for Free Cash Flow were $5.5 million (Q4 2025), $39.5 million (Q3 2025), and $11.9 million (Q2 2025) per Business Quant data.